Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sage-324
- Development stage
- Phase 2
- Lead developer
- Sage Therapeutics
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
SAGE-324 (also known as BIIB124) is an investigational oral neuroactive steroid and small molecule that acts as a positive allosteric modulator of the GABA A receptor. By binding to both synaptic and extrasynaptic GABA A receptors, it enhances inhibitory activity in the GABAergic system—the primary inhibitory neurotransmission system in the brain. This mechanism is relevant because dysregulation of GABA signaling has been implicated in essential tremor and other neurological disorders. SAGE-324 was developed by Sage Therapeutics, with Biogen as a collaborator for some indications. The drug reached Phase 2 clinical trials for essential tremor but was discontinued for this indication in 2024 due to lack of efficacy. It remains under investigation at earlier stages for epilepsy[1][3][4][5][6].
- Other names
- BIIB124BIIB-124BIIB 124
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on sage-324.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sage-324.